Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Medable has launched a digital-first Long-Term Follow-Up (LTFU) model intended for cell and gene therapy (CGT) trials.

Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...